Dyne Therapeutics [DYN] vs Vertex [VRTX] Detailed Stock Comparison

Dyne Therapeutics Inc.

NASDAQ
Loading...

Vertex Pharmaceuticals Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Dyne Therapeutics Inc. wins in 2 metrics, Vertex Pharmaceuticals Inc. wins in 12 metrics, with 0 ties. Vertex Pharmaceuticals Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Dyne Therapeutics Inc. Vertex Pharmaceuticals Inc. Better
P/E Ratio (TTM) N/A 28.40 N/A
Price-to-Book Ratio 3.26 5.92 Dyne Therapeutics Inc.
Debt-to-Equity Ratio 17.41 10.91 Vertex Pharmaceuticals Inc.
PEG Ratio -6.33 0.88 Vertex Pharmaceuticals Inc.
EV/EBITDA -4.78 21.78 Vertex Pharmaceuticals Inc.
Profit Margin (TTM) 0.00% 32.94% Vertex Pharmaceuticals Inc.
Operating Margin (TTM) 0.00% 39.60% Vertex Pharmaceuticals Inc.
EBITDA Margin (TTM) N/A 39.60% N/A
Return on Equity -55.71% 22.54% Vertex Pharmaceuticals Inc.
Return on Assets (TTM) -31.16% 12.16% Vertex Pharmaceuticals Inc.
Free Cash Flow (TTM) $-423.92M $3.19B Vertex Pharmaceuticals Inc.
1-Year Return 61.62% 1.24% Dyne Therapeutics Inc.
Price-to-Sales Ratio (TTM) N/A 9.22 N/A
Enterprise Value $2.23B $105.96B Vertex Pharmaceuticals Inc.
EV/Revenue Ratio N/A 8.83 N/A
Gross Profit Margin (TTM) N/A 85.39% N/A
Revenue per Share (TTM) N/A $47 N/A
Earnings per Share (Diluted) $-3.47 $15.32 Vertex Pharmaceuticals Inc.
Beta (Stock Volatility) 1.29 0.37 Vertex Pharmaceuticals Inc.
Short % of Float 13.63% 1.78% Vertex Pharmaceuticals Inc.

Dyne Therapeutics Inc. vs Vertex Pharmaceuticals Inc. Stock Performance Analysis

Loading Price Chart...

DYN
VRTX

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Dyne Therapeutics Inc.4.35%-0.94%1.58%23.22%-10.45%-2.76%
Vertex Pharmaceuticals Inc.0.76%-2.03%-0.35%-9.68%-7.51%-5.26%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Dyne Therapeutics Inc.61.62%43.93%6.56%-15.22%-15.22%-15.22%
Vertex Pharmaceuticals Inc.1.24%34.08%113.19%376.31%717.28%1,190.86%

Performance & Financial Health Analysis: Dyne Therapeutics Inc. vs Vertex Pharmaceuticals Inc.

MetricDYNVRTX
Market Information
Market Cap i$3.12B$109.45B
Market Cap CategoryMid capLarge cap
10 Day Avg. Volume i1,945,7091,057,061
90 Day Avg. Volume i2,268,5031,272,097
Last Close$17.99$428.34
52 Week Range$8.06 - $25.00$362.50 - $507.92
% from 52W High-28.04%-15.67%
All-Time High$47.45 (Aug 19, 2024)$519.88 (Nov 04, 2024)
% from All-Time High-62.09%-17.61%
Growth Metrics
Quarterly Revenue GrowthN/A0.10%
Quarterly Earnings GrowthN/A0.31%
Financial Health
Profit Margin (TTM) i0.00%0.33%
Operating Margin (TTM) i0.00%0.40%
Return on Equity (TTM) i-0.56%0.23%
Debt to Equity (MRQ) i17.4110.91
Cash & Liquidity
Book Value per Share (MRQ)$5.89$73.49
Cash per Share (MRQ)$6.73$26.01
Operating Cash Flow (TTM) i$-403,207,008$3.63B
Levered Free Cash Flow (TTM) i$-260,087,008$2.57B
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Dyne Therapeutics Inc. vs Vertex Pharmaceuticals Inc.

MetricDYN (Apr 24, 2026)VRTX (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) iN/A28.40
Forward P/E i-6.3319.95
PEG Ratio i-6.330.88
Price to Sales (TTM) iN/A9.22
Price to Book (MRQ) i3.265.92
Market Capitalization
Market Capitalization i$3.12B$109.45B
Enterprise Value i$2.23B$105.96B
Enterprise Value Metrics
Enterprise to Revenue iN/A8.83
Enterprise to EBITDA i-4.7821.78
Risk & Other Metrics
Beta i1.290.37
Book Value per Share (MRQ) i$5.89$73.49

Financial Statements Comparison: Dyne Therapeutics Inc. vs Vertex Pharmaceuticals Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricDYN (2025)VRTX (2025)
Revenue/Sales i012.00B
Cost of Goods Sold iN/A1.65B
COGS % of Revenue i-13.8%
Gross Profit iN/A10.35B
Gross Margin i-86.2%
Research & Development i398.33M4.04B
Operating Income (EBIT) i-468.18M4.55B
Operating Margin i-37.9%
EBITDA i-437.97M5.25B
EBITDA Margin i-43.7%
Pre-Tax Income i-446.21M4.64B
Pre-Tax Income % of Revenue i-38.7%
Income Tax iN/A690.00M
Income Tax % of Revenue i-5.7%
Net Income (Profit) i-446.21M3.95B
Profit Margin i-32.9%

Balance Sheet & Liquidity Metrics

MetricDYN (2025)VRTX (2025)
Cash & Equivalents i893.37M5.08B
Total Current Assets i1.13B11.20B
Total Current Assets % of Revenue i-93.3%
Total Current Liabilities i50.63M3.86B
Total Current Liabilities % of Revenue i-32.2%
Long-Term Debt i164.20M1.95B
Long-Term Debt % of Revenue i-16.3%
Total Shareholders Equity i972.13M18.67B
Retained Earnings i-1.40B13.56B
Retained Earnings % of Revenue i-113.0%
Property, Plant & Equipment i31.64M1.56B

Cash Flow Statement Comparison

MetricDYN (2025)VRTX (2025)
Operating Cash Flow i-402.42M3.77B
Operating Cash Flow % of Revenue i-31.4%
Capital Expenditures i-20.71M-437.60M
Free Cash Flow i-423.92M3.19B
FCF Margin i-26.6%
Debt Repayment iN/A-5.40M
Common Stock Repurchase iN/A-2.39B

Short Interest & Institutional Ownership Analysis

MetricDYNVRTX
Shares Short i20.47M4.02M
Short Ratio i7.682.80
Short % of Float i13.63%1.78%
Shares Outstanding i164.95M253.99M
Float Shares i155.36M253.24M
% Held by Insiders i0.66%0.21%
% Held by Institutions i115.13%97.60%
% Held by Public i-15.79%2.19%

Dividend Analysis & Yield Comparison: Dyne Therapeutics Inc. vs Vertex Pharmaceuticals Inc.

MetricDYNVRTX
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A